<div id="parent_top_div"><div id="between_article_content_1-0"></div><p>A US-based subsidiary of drugmaker Cipla is recalling over 400 cartons of generic anti-cancer medication due to a manufacturing issue, according to the US Food and Drug Administration (USFDA).</p>
<p>
	Warren (New Jersey)-based Cipla USA, Inc is recalling Nilotinib Capsules in two strengths (150 mg and 200 mg), the US health regulator said in its latest Enforcement Report.</p>
<p>
	The company is recalling the affected lot (271 and 164 cartons) due to &#34;failed tablet/capsule specifications&#34;, it stated.</p>
<p>
	Cipla USA, Inc initiated the Class III voluntary recall on February 18 this year.</p>
<p>
	According to the USFDA, a Class III recall is initiated in a &#34;situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences&#34;.</p><span style="height: 1px"> </span><div id="between_article_content_2-0"></div><div><div></div></div>
<p>
	Nilotinib works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps to stop or slow the spread of cancer cells.</p>
<p>
	India has the highest number of USFDA-compliant pharmaceutical plants outside of the US.</p>
<p>Indian pharmaceutical companies supply a substantial proportion of drugs to US residents, with four out of 10 of all prescriptions filled in the US in 2022 being supplied by Indian companies.</p></div>

坎伯蘭藥業

美國制藥 ETF - iShares

標普生物技術 ETF - SPDR

<p>Cipla USA, Inc. 是 Cipla 的子公司，因生產問題正在召回超過 400 箱 Nilotinib 膠囊（150 毫克和 200 毫克），這一消息由美國食品藥品監督管理局（USFDA）報告。該自願召回屬於 III 類，始於 2 月 18 日，表明接觸該產品不太可能導致不良健康後果。Nilotinib 用於阻止癌細胞的增殖。印度製藥公司在向美國市場供應藥物方面發揮着重要作用，2022 年它們填補了相當大比例的處方</p>

Cipla's US unit recalls 400+ cartons of generic anti-cancer drug: USFDA

Business Standard

2 倍做多納斯達克生物技術 ETF - ProShares

醫藥突破 ETF - ALPS

動態生物技術與基因組 ETF - Invesco

Citius Pharma

納斯達克生物科技指數 ETF - iShares Nasdaq

醫療業 ETF - Vanguard

Invesco Nasdaq Biotechnology ETF

基因改革 ETF - ARK

紐交所高增長板生物技術指數 ETF - First Trust

生物科技 ETF - VanEck Vectors

醫療業 ETF - SPDR

Cipla 的美國分公司召回 400 多箱仿製抗癌藥物：美國食品藥品監督管理局（USFDA）